secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2026-08-05T11:10:14+00:00
Accession:  0001193125-26-333834
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera Q2 net loss narrows to $61.2M; KT-621 AD trial data accelerated to year-end 2026
--------------------------------------------------------------------------------

- Net loss of $61.2M vs $76.6M in Q2 2025; collaboration revenue of $65.0M from Gilead ($45M) and Sanofi ($20M) milestones.
- Cash of $1.5B as of June 30, 2026, providing runway into 2029.
- KT-621 Phase 2b AD trial enrollment completed ~6 months early; topline data now expected by year-end 2026 (vs mid-2027).
- KT-579 Phase 1 healthy volunteer data expected 4Q26; lupus proof-of-concept trial planned.
- Appointed Felix Baker as Chairman, Terence Rooney as CMO; Sanofi initiated KT-485 Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/0001193125-26-333834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-333834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer